Globaler Markt für Cyclodextrine im Pharmabereich – Branchentrends und Prognose bis 2029

Inhaltsverzeichnis anfordernInhaltsverzeichnis anfordern Mit Analyst sprechen Mit Analyst sprechen Jetzt kaufenJetzt kaufen Vor dem Kauf anfragen Vorher anfragen Kostenloser Beispielbericht Kostenloser Beispielbericht

Globaler Markt für Cyclodextrine im Pharmabereich – Branchentrends und Prognose bis 2029

  • Pharmaceutical
  • Upcoming Reports
  • May 2022
  • Global
  • 350 Seiten
  • Anzahl der Tabellen: 540
  • Anzahl der Abbildungen: 79

Global Cyclodextrins In Pharma Market

Marktgröße in Milliarden USD

CAGR :  % Diagram

Diagramm Prognosezeitraum
2022 –2029
Diagramm Marktgröße (Basisjahr)
USD 270.40 Million
Diagramm Marktgröße (Prognosejahr)
USD 370.06 Million
Diagramm CAGR
%
Diagramm Wichtige Marktteilnehmer
  • Dummy1
  • Dummy2
  • Dummy3
  • Dummy4
  • Dummy5

>Globaler Markt für Cyclodextrine in der Pharmaindustrie , nach Typ (Β-Cyclodextrin, 2-Hydroxypropyl-Β-Cyclodextrin, Α-Cyclodextrin, γ-Cyclodextrin, zufällig methyliertes Β-Cyclodextrin, Sulfobutylether Β-Cyclodextrin, 2-Hydroxypropyl-Γ-Cyclodextrin), Struktur (Cyclodextrin-Konjugate, mukoadhäsive Arzneimittelträger, Cyclodextrin-Assoziate, amphiphile Cyclodextrine, andere), Beschaffenheit (hydrophil, hydrophob ), Form (fest, flüssig), Anwendung (Löslichkeit und Auflösung des Arzneimittels, Bioverfügbarkeit des Arzneimittels, Arzneimittelsicherheit, Arzneimittelstabilität, andere), Therapiebereich (Schmerztherapie, Herz-Kreislauf-Erkrankungen, Verhaltensstörungen, Krebstherapie, rheumatoide Arthritis, Epilepsie, Niemann-Pick-Krankheit Typ C (NPC), andere), Vertriebskanal (direkte Ausschreibung, Einzelhandelsverkauf, andere) – Branchentrends und Prognosen für 2029

Cyclodextrine im Pharmamarkt

Marktanalyse und Größe

In den letzten Jahren wird erwartet, dass der Markt für Cyclodextrine im Pharmabereich im Prognosezeitraum schnell wachsen wird. Cyclodextrine sind stärkebasierte Zuckermoleküle mit einem lipophilen Inneren und einer hydrophilen Außenhülle. Aufgrund seiner Anti-Aging-Eigenschaften ist Cyclodextrin bei Kosmetikherstellern sehr gefragt. Es wird häufig bei der Herstellung von Kosmetika und Körperpflegeprodukten wie Cremes, Gesichtsmasken und Lotionen verwendet und dürfte in den kommenden Jahren das Marktwachstum vorantreiben. Gleichzeitig dürfte die wachsende Beliebtheit von Nahrungsergänzungsmitteln zur Stärkung der allgemeinen Immunität auf der ganzen Welt im Prognosezeitraum das Marktwachstum vorantreiben.

Data Bridge Market Research analysiert, dass der Markt für Cyclodextrine in der Pharmaindustrie im Jahr 2021 einen Wert von 270,40 Millionen USD hatte und bis 2029 voraussichtlich 370,06 Millionen USD erreichen wird, was einer durchschnittlichen jährlichen Wachstumsrate (CAGR) von 4,00 % während des Prognosezeitraums von 2022 bis 2029 entspricht. Der vom Data Bridge Market Research-Team zusammengestellte Marktbericht umfasst eine eingehende Expertenanalyse, Patientenepidemiologie, Pipeline-Analyse, Preisanalyse und regulatorische Rahmenbedingungen.

Marktdefinition

Cyclodextrine sind eine Art komplexer zyklischer Zucker, der aus einem makrozyklischen Ring von Glucose-Untereinheiten besteht, die durch Alpha-1,4-glykosidische Bindungen miteinander verbunden sind. Cyclodextrin entsteht, wenn Stärke enzymatisch in einfache Moleküle zerlegt wird. Cyclodextrin wird in der pharmazeutischen und chemischen Industrie zunehmend als Lösungsmittelkomponente bei der Verabreichung von Medikamenten verwendet. Cyclodextrin wird verwendet, um die Wasserlöslichkeit, Stabilität und Bioverfügbarkeit von Arzneimitteln zu erhöhen, indem hydrophobe medizinische Moleküle in biologischen Systemen eingekapselt werden.

Berichtsumfang und Marktsegmentierung

Berichtsmetrik

Details

Prognosezeitraum

2022 bis 2029

Basisjahr

2021

Historische Jahre

2020 (Anpassbar auf 2019 – 2014)

Quantitative Einheiten

Umsatz in Mio. USD, Mengen in Einheiten, Preise in USD

Abgedeckte Segmente

Typ (Β-Cyclodextrin, 2-Hydroxypropyl-Β-Cyclodextrin, Α-Cyclodextrin, γ-Cyclodextrin, zufällig methyliertes Β-Cyclodextrin, Sulfobutylether-Β-Cyclodextrin, 2-Hydroxypropyl-Γ-Cyclodextrin), Struktur (Cyclodextrin-Konjugate, mukoadhäsive Arzneimittelträger, Cyclodextrin-Assoziate, amphiphile Cyclodextrine, andere), Beschaffenheit (hydrophil, hydrophob), Form (fest, flüssig), Anwendung (Löslichkeit und Auflösung des Arzneimittels, biologische Verfügbarkeit des Arzneimittels, Arzneimittelsicherheit, Arzneimittelstabilität, andere), Therapiebereich (Schmerztherapie, Herz-Kreislauf-Erkrankungen, Verhaltensstörungen, Krebstherapie, rheumatoide Arthritis, Epilepsie, Niemann-Pick-Krankheit Typ C (NPC), andere), Vertriebskanal (direkte Ausschreibung, Einzelhandelsverkauf, andere)

Abgedeckte Länder

USA, Kanada und Mexiko in Nordamerika, Deutschland, Frankreich, Großbritannien, Niederlande, Schweiz, Belgien, Russland, Italien, Spanien, Türkei, Restliches Europa in Europa, China, Japan, Indien, Südkorea, Singapur, Malaysia, Australien, Thailand, Indonesien, Philippinen, Restlicher Asien-Pazifik-Raum (APAC) in Asien-Pazifik (APAC), Saudi-Arabien, Vereinigte Arabische Emirate, Südafrika, Ägypten, Israel, Restlicher Naher Osten und Afrika (MEA) als Teil von Naher Osten und Afrika (MEA), Brasilien, Argentinien und Restliches Südamerika als Teil von Südamerika

Abgedeckte Marktteilnehmer

Cambrex Corporation (USA), Cayman Chemical (USA), Wellona Pharma (Indien), Wacker Chemie AG (Deutschland), Cyclolab (Ungarn), Tocopharm Co. Limited (China), Roquette Frères (Frankreich), Midas Pharma GmbH (Deutschland), Ligand Pharmaceuticals Incorporated (USA), Cyclo Therapeutics, Inc. (USA), Zibo Qianhui biological technology co., ltd (China), Xi'an Deli Biochemical Industry Co., Ltd (China), Merck KGaA (Deutschland), Otto Chemie Pvt. Ltd. (Indien), VIO CHEMICALS (Schweiz), Ashland (USA), TCI Chemicals (Indien) Pvt. Ltd. (Japan)

Marktchancen

  • Zunahme der Zahl der Schwellenmärkte
  • Steigerung der Forschungs- und Entwicklungsaktivitäten
  • Steigende Investitionen für die Entwicklung fortschrittlicher Technologien
  • Steigende Zahl an Arzneimittelzulassungen und -einführungen

Cyclodextrine in der Pharmaindustrie – Marktdynamik

Treiber

  • Zunehmender Konsum von Nahrungsergänzungsmitteln

Der steigende Konsum von Nahrungsergänzungsmitteln dürfte das Marktwachstum ankurbeln. Hilfsstoffe wie Cyclodextrin werden in pharmazeutischen und nutraceutischen Formulierungen verwendet. Infolge der COVID-19-Pandemie haben Ärzte Patienten eine Vielzahl antiviraler Medikamente verschrieben, um ihnen zu helfen, das Virus frühzeitig zu bekämpfen. Der zunehmende Einsatz dieser Medikamente hat den Cyclodextrinkonsum angekurbelt und das Marktwachstum im gesamten Prognosezeitraum vorangetrieben.

  • Steigende Investitionen in die Gesundheitsinfrastruktur

Ein weiterer wichtiger Faktor, der die Wachstumsrate von Cyclodextrinen auf dem Pharmamarkt beeinflusst, sind die steigenden Gesundheitsausgaben, die zur Verbesserung der Infrastruktur beitragen. Darüber hinaus zielen verschiedene Regierungsorganisationen darauf ab, die Gesundheitsinfrastruktur durch eine Erhöhung der Mittel zu verbessern, was die Marktdynamik weiter beeinflussen wird.

Darüber hinaus werden zunehmende Initiativen öffentlicher und privater Organisationen zur Sensibilisierung den Markt für Cyclodextrine im Pharmabereich erweitern. Darüber hinaus werden die sich schnell ändernde Einstellung der Verbraucher zur Gesundheit und die zunehmende Verwendung von Cyclodextrinen bei Nierenerkrankungen ebenfalls zu einer Ausweitung des Marktes für Cyclodextrine im Pharmabereich führen.

Gelegenheiten

  • Steigerung der Forschungs- und Entwicklungsaktivitäten       

Darüber hinaus wird das Marktwachstum durch eine Zunahme der Forschungs- und Entwicklungsaktivitäten vorangetrieben. Dies wird dem Wachstum des Cyclodextrinmarktes in der Pharmaindustrie günstige Möglichkeiten bieten. Darüber hinaus werden steigende Arzneimittelzulassungen und -einführungen das Marktwachstum weiter vorantreiben. 

Darüber hinaus werden steigende Investitionen in die Entwicklung fortschrittlicher Technologien und eine Zunahme der Zahl aufstrebender Märkte im Prognosezeitraum günstige Chancen für das Wachstum des Marktes für Cyclodextrine in der Pharmaindustrie bieten.

Einschränkungen/Herausforderungen

Andererseits werden die hohen Kosten, die mit der Arzneimittelverteilung und -entwicklung verbunden sind, das Marktwachstum behindern. Der Mangel an Fachkräften und die fehlende Gesundheitsinfrastruktur in Entwicklungsländern werden den Markt für Cyclodextrine in der Pharmaindustrie vor Herausforderungen stellen. Darüber hinaus werden strenge Regulierungsrichtlinien in Verbindung mit den Hindernissen bei der Durchführung diagnostischer Tests das Marktwachstum im Prognosezeitraum 2022–2029 einschränken und weiter behindern.

Dieser Marktbericht zu Cyclodextrinen in der Pharmaindustrie enthält Einzelheiten zu neuen Entwicklungen, Handelsvorschriften, Import-Export-Analysen, Produktionsanalysen, Optimierung der Wertschöpfungskette, Marktanteilen, Auswirkungen inländischer und lokaler Marktteilnehmer, analysiert Chancen in Bezug auf neue Einnahmequellen, Änderungen der Marktvorschriften, strategische Marktwachstumsanalysen, Marktgröße, Kategoriemarktwachstum, Anwendungsnischen und -dominanz, Produktzulassungen, Produkteinführungen, geografische Expansionen und technologische Innovationen auf dem Markt. Um weitere Informationen zum Markt für Cyclodextrine in der Pharmaindustrie zu erhalten, wenden Sie sich an Data Bridge Market Research, um einen Analystenbericht zu erhalten. Unser Team hilft Ihnen dabei, eine fundierte Marktentscheidung zu treffen, um Marktwachstum zu erzielen.

Patientenepidemiologische Analyse

Cyclodextrine im Pharmamarkt bietet Ihnen auch eine detaillierte Marktanalyse für Patientenanalyse, Prognose und Heilung. Prävalenz, Inzidenz, Mortalität und Adhärenzraten sind einige der im Bericht verfügbaren Datenvariablen. Direkte oder indirekte Auswirkungsanalysen der Epidemiologie auf das Marktwachstum werden analysiert, um ein robusteres und kohortenbasiertes multivariates statistisches Modell zur Prognose des Marktes in der Wachstumsphase zu erstellen.

Auswirkungen von COVID-19 auf Cyclodextrine im Pharmamarkt

Seit seinem Auftreten im Dezember 2019 hat sich das COVID-19-   Virus in fast allen Ländern der Erde verbreitet, was die Weltgesundheitsorganisation (WHO) dazu veranlasste, es zu einem öffentlichen Gesundheitsnotfall zu erklären. COVID-19, ein neues Coronavirus, wurde als Auslöser von Lungenentzündungen identifiziert. Dieses Virus verbreitete sich schnell auf der ganzen Welt und tötete eine große Zahl von Menschen. COVID-19 wurde im März 2020 von der Weltgesundheitsorganisation (WHO) als globale Pandemie bezeichnet und strenge Maßnahmen zur Verhinderung der Ausbreitung der Krankheit empfohlen. Seitdem hat die Pandemie den Ausbau des Gesundheitssektors verzögert und die Lieferkette unterbrochen. Darüber hinaus haben Regierungen in vielen Ländern landesweite Ausgangssperren verhängt, um die Ausbreitung von COVID-19 zu stoppen. Ebenso hatten Gesundheitsorganisationen in zahlreichen Ländern auf der ganzen Welt Schwierigkeiten, ihre Lieferkettenaktivitäten fortzusetzen. Der Markt für Cyclodextrine in der Pharmaindustrie wurde durch die Langsamkeit der Lieferkette behindert. Da COVID-19-Impfstoffe nun jedoch leicht verfügbar sind, versuchen zahlreiche Behörden sicherzustellen, dass lebensrettende Medikamente und Impfstoffe ohne Unterbrechung geliefert werden. Infolgedessen wird für die Zukunft mit einer Stabilisierung des Marktes gerechnet.

Globaler Markt für Cyclodextrine in der Pharmaindustrie

Der Markt für Cyclodextrine in der Pharmaindustrie ist nach Typ, Struktur, Art, Form, Anwendung, therapeutischen Bereichen und Vertriebskanälen segmentiert. Das Wachstum dieser Segmente hilft Ihnen bei der Analyse schwacher Wachstumssegmente in den Branchen und bietet den Benutzern einen wertvollen Marktüberblick und Markteinblicke, die ihnen bei der strategischen Entscheidungsfindung zur Identifizierung der wichtigsten Marktanwendungen helfen.

Typ

  • Β Cyclodextrin
  • 2-Hydroxypropyl-Β-Cyclodextrin
  • Α-Cyclodextrin
  • γ-Cyclodextrin
  • Zufällig methyliertes Β-Cyclodextrin
  • Sulfobutylether Β-Cyclodextrin
  • 2-Hydroxypropyl-Γ-Cyclodextrin

Struktur

  • Cyclodextrin-Konjugate
  • Mukoadhäsive Arzneimittelträger
  • Cyclodextrin Associates
  • Amphiphile Cyclodextrine
  • Sonstiges

Natur

  • Hydrophil
  • Hydrophob

Bilden

  • Solide
  • Flüssig

Anwendung

  • Löslichkeit und Auflösung des Arzneimittels
  • Bioverfügbarkeit des Arzneimittels
  • Arzneimittelsicherheit
  • Arzneimittelstabilität
  • Sonstiges

Therapeutischer Bereich

  • Schmerztherapie
  • Herz-Kreislauf-Erkrankungen
  • Verhaltensstörung
  • Krebstherapie
  • Rheumatoide Arthritis
  • Epilepsie
  • Niemann-Pick-Krankheit Typ C (NPC)
  • Sonstiges

Vertriebskanal

  • Direkte Ausschreibung
  • Einzelhandelsumsätze
  • Sonstiges

Cyclodextrine in der Pharmaindustrie – Regionale Analyse/Einblicke

Der Markt für Cyclodextrine in der Pharmaindustrie wird analysiert und es werden Einblicke in die Marktgröße und Trends nach Land, Typ, Struktur, Art, Form, Anwendung, Therapiebereichen und Vertriebskanal wie oben angegeben bereitgestellt.

Die im Bericht über Cyclodextrine in der Pharmaindustrie abgedeckten Länder sind die USA, Kanada und Mexiko in Nordamerika, Deutschland, Frankreich, Großbritannien, Niederlande, Schweiz, Belgien, Russland, Italien, Spanien, Türkei, Restliches Europa in Europa, China, Japan, Indien, Südkorea, Singapur, Malaysia, Australien, Thailand, Indonesien, Philippinen, Restlicher Asien-Pazifik-Raum (APAC) in Asien-Pazifik (APAC), Saudi-Arabien, Vereinigte Arabische Emirate, Südafrika, Ägypten, Israel, Restlicher Naher Osten und Afrika (MEA) als Teil des Nahen Ostens und Afrikas (MEA), Brasilien, Argentinien und Restliches Südamerika als Teil Südamerikas

Nordamerika dominiert den Cyclodextrin-Markt aufgrund neuer Cyclodextrin-führender Arzneimittel in der Pharmakologie dieser Region. Darüber hinaus werden steigende Gesundheitsausgaben und die wachsende Nachfrage nach krankheitsspezifischen Behandlungen das Marktwachstum in dieser Region weiter vorantreiben.

Der asiatisch-pazifische Raum dürfte im Prognosezeitraum 2022 bis 2029 aufgrund der steigenden Verbrauchernachfrage nach Cyclodextrinverbindungen für pharmazeutische Produkte in dieser Region wachsen. Darüber hinaus werden die Entwicklung der Gesundheitsinfrastruktur und zunehmende Regierungsinitiativen die Wachstumsrate des Marktes in dieser Region weiter vorantreiben.

Der Länderabschnitt des Berichts enthält auch Angaben zu einzelnen marktbeeinflussenden Faktoren und Änderungen der Regulierung auf dem Inlandsmarkt, die sich auf die aktuellen und zukünftigen Trends des Marktes auswirken. Datenpunkte wie Downstream- und Upstream-Wertschöpfungskettenanalysen, technische Trends und Porters Fünf-Kräfte-Analyse sowie Fallstudien sind einige der Anhaltspunkte, die zur Prognose des Marktszenarios für einzelne Länder verwendet werden. Bei der Bereitstellung von Prognoseanalysen der Länderdaten werden auch die Präsenz und Verfügbarkeit globaler Marken und ihre Herausforderungen aufgrund großer oder geringer Konkurrenz durch lokale und inländische Marken sowie die Auswirkungen inländischer Zölle und Handelsrouten berücksichtigt.   

Wettbewerbsumfeld und Cyclodextrine in der Pharmaindustrie Marktanteilsanalyse

Die Wettbewerbslandschaft des Marktes für Cyclodextrine in der Pharmaindustrie liefert Details nach Wettbewerbern. Die enthaltenen Details sind Unternehmensübersicht, Unternehmensfinanzen, erzielter Umsatz, Marktpotenzial, Investitionen in Forschung und Entwicklung, neue Marktinitiativen, globale Präsenz, Produktionsstandorte und -anlagen, Produktionskapazitäten, Stärken und Schwächen des Unternehmens, Produkteinführung, Produktbreite und -umfang, Anwendungsdominanz. Die oben angegebenen Datenpunkte beziehen sich nur auf den Fokus der Unternehmen in Bezug auf Cyclodextrine im Pharmamarkt.

Zu den wichtigsten Akteuren auf dem Markt für Cyclodextrine in der Pharmaindustrie zählen:

  • Cambrex Corporation (USA)
  • Cayman Chemical (USA)
  • Wellona Pharma (Indien)
  • Wacker Chemie AG (Deutschland)
  • Cyclolab (Ungarn)
  • Tocopharm Co. Limited (China)
  • Roquette Frères (Frankreich)
  • Midas Pharma GmbH (Deutschland)
  • Ligand Pharmaceuticals Incorporated (USA)
  • Cyclo Therapeutics, Inc. (USA)
  • Zibo Qianhui Biologische Technologie Co., Ltd. (China)
  • Xi'an Deli Biochemical Industry Co., Ltd. (China)
  • Merck KGaA (Deutschland)
  • Otto Chemie Pvt. Ltd. (Indien)
  • VIO CHEMICALS (Schweiz)
  • Ashland (USA)
  • TCI Chemicals (Indien) Pvt. Ltd. (Japan)


SKU-

Erhalten Sie Online-Zugriff auf den Bericht zur weltweit ersten Market Intelligence Cloud

  • Interaktives Datenanalyse-Dashboard
  • Unternehmensanalyse-Dashboard für Chancen mit hohem Wachstumspotenzial
  • Zugriff für Research-Analysten für Anpassungen und Abfragen
  • Konkurrenzanalyse mit interaktivem Dashboard
  • Aktuelle Nachrichten, Updates und Trendanalyse
  • Nutzen Sie die Leistungsfähigkeit der Benchmark-Analyse für eine umfassende Konkurrenzverfolgung
Demo anfordern

Inhaltsverzeichnis

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF GLOBAL CYCLODEXTRINS IN PHARMA MARKET

1.4 LIMITATIONS

1.5 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 CURRENCY AND PRICING

2.5 DBMR TRIPOD DATA VALIDATION MODEL

2.6 MULTIVARIATE MODELLING

2.7 MARKET APPLICATION COVERAGE GRID

2.8 THERAPEUTIC AREAS LIFELINE CURVE

2.9 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.1 DBMR MARKET POSITION GRID

2.11 VENDOR SHARE ANALYSIS

2.12 SECONDARY SOURCES

2.13 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PIPELINE ANALYSIS

5 REGULATIONS

5.1 FDA

5.2 JAPAN

6 IMPACT OF COVID-19 ON GLOBAL CYCLODEXTRIN IN PHARMA MARKET

6.1 PRICE IMPACT

6.2 IMPACT ON DEMAND

6.3 IMPACT ON SUPPLY CHAIN

6.4 KEY INITIATIVES BY MARKET PLAYERS DURING COVID-19

6.5 CONCLUSION

7 MARKET OVERVIEW

7.1 DRIVERS

7.1.1 INCREASING BIO AVAILABILITY OF POOR WATER SOLUBLE DRUGS

7.1.2 INCREASING DRUG STABILITY

7.1.3 USE OF CYCLODEXTRIN IN DRUG DELIVERY

7.1.4 LAUNCH OF FINISHED PRODUCTS OF CYCLODEXTRIN

7.1.5 RISING PREVALENCE OF CHRONIC DISEASES

7.2 RESTRAINTS

7.2.1 HIGH COSTS OF CYCLODEXTRIN

7.2.2 TOXICITY STUDIES OF CYCLODEXTRINS

7.3 OPPORTUNITIES

7.3.1 INCREASING RESEARCH OF CYCLODEXTRIN IN COVID-19 TREATMENT

7.3.2 RISING USE OF CYCLODEXTRIN IN RENAL DISEASES

7.3.3 RISING INVESTMENT ON RESEARCH ACTIVITIES

7.3.4 INCREASES AWARENESS ABOUT THE USE OF CYCLODEXTRIN IN PHARMA INDUSTRY

7.4 CHALLENGES

7.4.1 LIMITATION OF CYCLODEXTRIN IN OPTHALMIC USE

7.4.2 USE OF VARIOUS TECHNIQUES IN MANUFACTURING CYCLODEXTRIN

8 GLOBAL CYCLODEXTRINS IN PHARMA MARKET, BY TYPE

8.1 OVERVIEW

8.1.1 Β CYCLODEXTRIN

8.1.2 2-HYDROXYPROPYL-Β-CYCLODEXTRIN

8.1.3 Α CYCLODEXTRIN

8.1.4 Γ-CYCLODEXTRIN

8.1.5 RANDOMLY METHYLATED Β-CYCLODEXTRIN

8.1.6 SULFOBUTYLETHER Β-CYCLODEXTRIN

8.1.7 2-HYDROXYPROPYL-Γ-CYCLODEXTRIN

9 GLOBAL CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE

9.1 OVERVIEW

9.2 CYCLODEXTRIN CONJUGATES

9.2.1 POLYMERS

9.2.2 NANOSPONGES

9.3 MUCOADHESIVE DRUG CARRIERS

9.3.1 POLYETHYLENE-GLYCOL

9.3.2 CHITOSAN

9.3.3 ALGINATE

9.4 CYCLODEXTRIN ASSOCIATES

9.4.1 POLYPSEUDOROTAXANES

9.4.2 POLYROTAXANES

9.5 AMPHIPHILIC CYCLODEXTRINS

9.5.1 POLYSUBSTITUTED

9.5.2 MONOSUBSTITUTED

9.6 OTHERS

10 GLOBAL CYCLODEXTRINS IN PHARMA MARKET, BY FORM

10.1 OVERVIEW

10.2 SOLID

10.3 LIQUID

11 GLOBAL CYCLODEXTRINS IN PHARMA MARKET, BY NATURE

11.1 OVERVIEW

11.2 HYDROPHILIC

11.3 HYDROPHOBIC

12 GLOBAL CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION

12.1 OVERVIEW

12.2 DRUG SOLUBILITY AND DISSOLUTION

12.3 DRUG BIOAVAILABILITY

12.4 DRUG SAFETY

12.5 DRUG STABILITY

12.6 OTHERS

13 GLOBAL CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS

13.1 OVERVIEW

13.2 PAIN MANAGEMENT

13.3 CARDIOVASCULAR DISEASES

13.4 BEHAVIORAL DISORDER

13.5 CANCER THERAPY

13.6 RHEUMATOID ARTHRITIS

13.7 EPILEPSY

13.8 NIEMANN PICK DISEASE TYPE C (NPC)

13.9 OTHERS

14 GLOBAL CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL

14.1 OVERVIEW

14.2 DIRECT TENDER

14.3 RETAIL SALES

14.4 OTHERS

15 GLOBAL CYCLODEXTRINS IN PHARMA MARKET, BY GEOGRAPHY

15.1 OVERVIEW

15.2 NORTH AMERICA

15.2.1 U.S.

15.2.2 CANADA

15.2.3 MEXICO

15.3 EUROPE

15.3.1 GERMANY

15.3.2 FRANCE

15.3.3 U.K

15.3.4 ITALY

15.3.5 NETHERLANDS

15.3.6 SPAIN

15.3.7 RUSSIA

15.3.8 SWITZERLAND

15.3.9 BELGIUM

15.3.10 TURKEY

15.3.11 AUSTRIA

15.3.12 NORWAY

15.3.13 HUNGARY

15.3.14 LITHUANIA

15.3.15 IRELAND

15.3.16 POLAND

15.3.17 REST OF EUROPE

15.4 ASIA-PACIFIC

15.4.1 JAPAN

15.4.2 CHINA

15.4.3 INDIA

15.4.4 SOUTH KOREA

15.4.5 AUSTRALIA

15.4.6 SINGAPORE

15.4.7 MALAYSIA

15.4.8 THAILAND

15.4.9 INDONESIA

15.4.10 PHILIPPINES

15.4.11 VIETNAM

15.4.12 REST OF ASIA-PACIFIC

15.5 SOUTH AMERICA

15.5.1 BRAZIL

15.5.2 ARGENTINA

15.5.3 PERU

15.5.4 REST OF SOUTH AMERICA

15.6 MIDDLE EAST & AFRICA

15.6.1 SAUDI ARABIA

15.6.2 SOUTH AFRICA

15.6.3 UAE

15.6.4 ISRAEL

15.6.5 EGYPT

15.6.6 KUWAIT

15.6.7 REST OF MIDDLE EAST & AFRICA

16 GLOBAL CYCLODEXTRINS IN PHARMA MARKET, COMPANY LANDSCAPE

16.1 COMPANY SHARE ANALYSIS: GLOBAL

16.2 COMPANY SHARE ANALYSIS: NORTH AMERICA

16.3 COMPANY SHARE ANALYSIS: EUROPE

16.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC

17 SWOT

18 COMPANY PROFILE

18.1 ROQUETTE FRÈRES

18.1.1 COMPANY SNAPSHOT

18.1.2 COMPANY SHARE ANALYSIS

18.1.3 PRODUCT PORTFOLIO

18.1.4 RECENT DEVELOPMENTS

18.2 LIGAND PHARMACEUTICALS INCORPORATED

18.2.1 COMPANY SNAPSHOT

18.2.2 REVENUE ANALYSIS

18.2.3 COMPANY SHARE ANALYSIS

18.2.4 TECHNOLOGY PORTFOLIO

18.2.5 RECENT DEVELOPMENTS

18.3 WACKER CHEMIE AG

18.3.1 COMPANY SNAPSHOT

18.3.2 REVENUE ANALYSIS

18.3.3 COMPANY SHARE ANALYSIS

18.3.4 PRODUCT PORTFOLIO

18.3.5 RECENT DEVELOPMENTS

18.4 MERCK KGAA

18.4.1 COMPANY SNAPSHOT

18.4.2 REVENUE ANALYSIS

18.4.3 COMPANY SHARE ANALYSIS

18.4.4 PRODUCT PORTFOLIO

18.4.5 RECENT DEVELOPMENTS

18.5 CYCLOLAB

18.5.1 COMPANY SNAPSHOT

18.5.2 PRODUCT PORTFOLIO

18.5.3 RECENT DEVELOPMENTS

18.6 CAMBREX CORPORATION

18.6.1 COMPANY SNAPSHOT

18.6.2 PRODUCT PORTFOLIO

18.6.3 RECENT DEVELOPMENTS

18.7 CAYMAN CHEMICAL

18.7.1 COMPANY SNAPSHOT

18.7.2 PRODUCT PORTFOLIO

18.7.3 RECENT DEVELOPMENTS

18.8 CYCLO THERAPEUTICS, INC.

18.8.1 COMPANY SNAPSHOT

18.8.2 REVENUE ANALYSIS

18.8.3 PRODUCT PORTFOLIO

18.8.4 RECENT DEVELOPMENTS

18.9 MIDAS PHARMA GMBH

18.9.1 COMPANY SNAPSHOT

18.9.2 PRODUCT PORTFOLIO

18.9.3 RECENT DEVELOPMENT

18.1 TOCOPHARM CO. LIMITED

18.10.1 COMPANY SNAPSHOT

18.10.2 PRODUCT PORTFOLIO

18.10.3 RECENT DEVELOPMENT

18.11 WELLONA PHARMA

18.11.1 COMPANY SNAPSHOT

18.11.2 PRODUCT PORTFOLIO

18.11.3 RECENT DEVELOPMENT

18.12 XI'AN DELI BIOCHEMICAL INDUSTRY CO.,LTD.

18.12.1 COMPANY SNAPSHOT

18.12.2 PRODUCT PORTFOLIO

18.12.3 RECENT DEVELOPMENT

18.13 ZIBO QIANHUI BIOLOGICAL TECHNOLOGY CO.,LTD

18.13.1 COMPANY SNAPSHOT

18.13.2 PRODUCT PORTFOLIO

18.13.3 RECENT DEVELOPMENT

19 QUESTIONNAIRE

20 RELATED REPORTS

Tabellenverzeichnis

LIST OF TABLES 

TABLE 1 CURRENT ANTIVIRAL DRUGS TESTED OR IN DEVELOPMENT FOR TREATMENT OF COVID-19 AND PROPOSED CYCLODEXTRINS FOR FORMULATION ENHANCEMENT

TABLE 2 PRICE OF 25G BETA-CYCLODEXTRIN

TABLE 3 PRICE OF 100G BETA-CYCLODEXTRIN

TABLE 4 GLOBAL CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2017-2027 (USD THOUSAND)

TABLE 5 GLOBA Β CYCLODEXTRIN IN CYCLODEXTRINS IN PHARMA MARKET, BY REGION, 2017-2027 (USD THOUSAND)

TABLE 6 GLOBAL 2-HYDROXYPROPYL-Β-CYCLODEXTRIN IN CYCLODEXTRINS IN PHARMA MARKET, BY REGION, 2017-2027 (USD THOUSAND)

TABLE 7 GLOBAL Α CYCLODEXTRIN IN CYCLODEXTRINS IN PHARMA MARKET, BY REGION, 2017-2027 (USD THOUSAND)

TABLE 8 GLOBAL Γ-CYCLODEXTRIN IN CYCLODEXTRINS IN PHARMA MARKET, BY REGION, 2017-2027 (USD THOUSAND)

TABLE 9 GLOBAL RANDOMLY METHYLATED Β-CYCLODEXTRIN IN CYCLODEXTRINS IN PHARMA MARKET, BY REGION, 2017-2027 (USD THOUSAND)

TABLE 10 GLOBAL SULFOBUTYLETHER Β-CYCLODEXTRIN IN CYCLODEXTRINS IN PHARMA MARKET, BY REGION, 2017-2027 (USD THOUSAND)

TABLE 11 GLOBAL 2-HYDROXYPROPYL-Γ-CYCLODEXTRIN IN CYCLODEXTRINS IN PHARMA MARKET, BY REGION, 2017-2027 (USD THOUSAND)

TABLE 12 GLOBAL CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE 2019-2027 (USD THOUSAND)

TABLE 13 GLOBAL CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY REGION 2018-2027 (USD THOUSAND)

TABLE 14 GLOBAL CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 15 GLOBAL MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY REGION 2018-2027 (USD THOUSAND)

TABLE 16 GLOBAL MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 17 GLOBAL CYCLODEXTRINS ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY REGION, 2017-2027 (USD THOUSAND)

TABLE 18 GLOBAL CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 19 GLOBAL AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY REGION, 2017-2027 (USD THOUSAND)

TABLE 20 GLOBAL AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 21 GLOBAL OTHERS IN CYCLODEXTRINS IN PHARMA MARKET, BY REGION, 2017-2027 (USD THOUSAND)

TABLE 22 GLOBAL CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2019-2027 (USD THOUSAND)

TABLE 23 GLOBAL SOLID IN CYCLODEXTRINS IN PHARMA MARKET, BY REGION, 2017-2027 (USD THOUSAND)

TABLE 24 GLOBAL LIQUID IN CYCLODEXTRINS IN PHARMA MARKET, BY REGION, 2017-2027 (USD THOUSAND)

TABLE 25 GLOBAL CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2019-2027 (USD THOUSAND)

TABLE 26 GLOBAL HYDROPHILIC IN CYCLODEXTRINS IN PHARMA MARKET, BY REGION, 2017-2027 (USD THOUSAND)

TABLE 27 GLOBAL HYDROPHOBIC IN CYCLODEXTRINS IN PHARMA MARKET, BY REGION, 2017-2027 (USD THOUSAND)

TABLE 28 GLOBAL CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2019-2027 (USD THOUSAND)

TABLE 29 GLOBAL DRUG SOLUBILITY AND DISSOLUTION IN CYCLODEXTRINS IN PHARMA MARKET, BY REGION, 2019-2027 (USD THOUSAND)

TABLE 30 GLOBAL DRUG BIOAVAILABILITY IN CYCLODEXTRINS IN PHARMA MARKET, BY REGION, 2019-2027 (USD THOUSAND)

TABLE 31 GLOBAL DRUG SAFETY IN CYCLODEXTRINS IN PHARMA MARKET, BY REGION, 2019-2027 (USD THOUSAND)

TABLE 32 GLOBAL DRUG STABILITY IN CYCLODEXTRINS IN PHARMA MARKET, BY REGION, 2019-2027 (USD THOUSAND)

TABLE 33 GLOBAL OTHERS IN CYCLODEXTRINS IN PHARMA MARKET, BY REGION, 2019-2027 (USD THOUSAND)

TABLE 34 GLOBAL CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2017-2027 (USD THOUSAND)

TABLE 35 GLOBA PAIN MANAGEMENT IN CYCLODEXTRINS IN PHARMA MARKET, BY REGION, 2017-2027 (USD THOUSAND)

TABLE 36 GLOBA CARDIOVASCULAR DISEASES IN CYCLODEXTRINS IN PHARMA MARKET, BY REGION, 2017-2027 (USD THOUSAND)

TABLE 37 GLOBA BEHAVIORAL DISORDER IN CYCLODEXTRINS IN PHARMA MARKET, BY REGION, 2017-2027 (USD THOUSAND)

TABLE 38 GLOBA CANCER THERAPY IN CYCLODEXTRINS IN PHARMA MARKET, BY REGION, 2017-2027 (USD THOUSAND)

TABLE 39 GLOBA RHEUMATOID ARTHRITIS IN CYCLODEXTRINS IN PHARMA MARKET, BY REGION, 2017-2027 (USD THOUSAND)

TABLE 40 GLOBA EPILEPSY IN CYCLODEXTRINS IN PHARMA MARKET, BY REGION, 2017-2027 (USD THOUSAND)

TABLE 41 GLOBA NIEMANN PICK DISEASE TYPE C (NPC) IN CYCLODEXTRINS IN PHARMA MARKET, BY REGION, 2017-2027 (USD THOUSAND)

TABLE 42 GLOBA OTHERS IN CYCLODEXTRINS IN PHARMA MARKET, BY REGION, 2017-2027 (USD THOUSAND)

TABLE 43 GLOBAL CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2019-2027 (USD THOUSAND)

TABLE 44 GLOBAL DIRECT TENDER IN CYCLODEXTRINS IN PHARMA MARKET, BY REGION, 2019-2027 (USD THOUSAND)

TABLE 45 GLOBAL RETAIL SALES IN CYCLODEXTRINS IN PHARMA MARKET, BY REGION, 2019-2027 (USD THOUSAND)

TABLE 46 GLOBAL OTHERS IN CYCLODEXTRINS IN PHARMA MARKET, BY REGION, 2019-2027 (USD THOUSAND)

TABLE 47 GLOBAL CYCLODEXTRINS IN PHARMA MARKET, BY REGION, 2018-2027 (USD THOUSAND)

TABLE 48 NORTH AMERICA CYCLODEXTRINS IN PHARMA MARKET, BY COUNTRY, 2018-2027 (USD THOUSAND)

TABLE 49 NORTH AMERICA CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)

TABLE 50 NORTH AMERICA CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 51 NORTH AMERICA CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 52 NORTH AMERICA CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 53 NORTH AMERICA MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 54 NORTH AMERICA AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 55 NORTH AMERICA CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)

TABLE 56 NORTH AMERICA CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)

TABLE 57 NORTH AMERICA CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)

TABLE 58 NORTH AMERICA CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)

TABLE 59 NORTH AMERICA CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)

TABLE 60 U.S. CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)

TABLE 61 U.S. CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 62 U.S. CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 63 U.S. CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 64 U.S. MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 65 U.S. AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 66 U.S. CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)

TABLE 67 U.S. CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)

TABLE 68 U.S. CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)

TABLE 69 U.S. CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)

TABLE 70 U.S. CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)

TABLE 71 CANADA CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)

TABLE 72 CANADA CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 73 CANADA CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 74 CANADA CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 75 CANADA MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 76 CANADA AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 77 CANADA CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)

TABLE 78 CANADA CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)

TABLE 79 CANADA CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)

TABLE 80 CANADA CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)

TABLE 81 CANADA CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)

TABLE 82 MEXICO CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)

TABLE 83 MEXICO CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 84 MEXICO CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 85 MEXICO CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 86 MEXICO MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 87 MEXICO AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 88 MEXICO CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)

TABLE 89 MEXICO CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)

TABLE 90 MEXICO CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)

TABLE 91 MEXICO CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)

TABLE 92 MEXICO CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)

TABLE 93 EUROPE CYCLODEXTRINS IN PHARMA MARKET, BY COUNTRY, 2018-2027 (USD THOUSAND)

TABLE 94 EUROPE CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)

TABLE 95 EUROPE CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 96 EUROPE CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 97 EUROPE CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 98 EUROPE MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 99 EUROPE AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 100 EUROPE CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)

TABLE 101 EUROPE CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)

TABLE 102 EUROPE CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)

TABLE 103 EUROPE CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)

TABLE 104 EUROPE CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)

TABLE 105 GERMANY CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)

TABLE 106 GERMANY CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 107 GERMANY CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 108 GERMANY CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 109 GERMANY MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 110 GERMANY AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 111 GERMANY CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)

TABLE 112 GERMANY CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)

TABLE 113 GERMANY CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)

TABLE 114 GERMANY CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)

TABLE 115 GERMANY CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)

TABLE 116 FRANCE CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)

TABLE 117 FRANCE CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 118 FRANCE CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 119 FRANCE CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 120 FRANCE MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 121 FRANCE AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 122 FRANCE CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)

TABLE 123 FRANCE CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)

TABLE 124 FRANCE CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)

TABLE 125 FRANCE CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)

TABLE 126 FRANCE CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)

TABLE 127 U.K CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)

TABLE 128 U.K CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 129 U.K CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 130 U.K CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 131 U.K MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 132 U.K AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 133 U.K CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)

TABLE 134 U.K CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)

TABLE 135 U.K CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)

TABLE 136 U.K CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)

TABLE 137 U.K CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)

TABLE 138 ITALY CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)

TABLE 139 ITALY CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 140 ITALY CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 141 ITALY CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 142 ITALY MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 143 ITALY AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 144 ITALY CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)

TABLE 145 ITALY CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)

TABLE 146 ITALY CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)

TABLE 147 ITALY CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)

TABLE 148 ITALY CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)

TABLE 149 NETHERLANDS CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)

TABLE 150 NETHERLANDS CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 151 NETHERLANDS CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 152 NETHERLANDS CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 153 NETHERLANDS MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 154 NETHERLANDS AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 155 NETHERLANDS CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)

TABLE 156 NETHERLANDS CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)

TABLE 157 NETHERLANDS CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)

TABLE 158 NETHERLANDS CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)

TABLE 159 NETHERLANDS CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)

TABLE 160 SPAIN CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)

TABLE 161 SPAIN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 162 SPAIN CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 163 SPAIN CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 164 SPAIN MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 165 SPAIN AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 166 SPAIN CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)

TABLE 167 SPAIN CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)

TABLE 168 SPAIN CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)

TABLE 169 SPAIN CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)

TABLE 170 SPAIN CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)

TABLE 171 RUSSIA CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)

TABLE 172 RUSSIA CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 173 RUSSIA CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 174 RUSSIA CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 175 RUSSIA MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 176 RUSSIA AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 177 RUSSIA CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)

TABLE 178 RUSSIA CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)

TABLE 179 RUSSIA CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)

TABLE 180 RUSSIA CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)

TABLE 181 RUSSIA CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)

TABLE 182 SWITZERLAND CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)

TABLE 183 SWITZERLAND CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 184 SWITZERLAND CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 185 SWITZERLAND CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 186 SWITZERLAND MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 187 SWITZERLAND AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 188 SWITZERLAND CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)

TABLE 189 SWITZERLAND CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)

TABLE 190 SWITZERLAND CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)

TABLE 191 SWITZERLAND CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)

TABLE 192 SWITZERLAND CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)

TABLE 193 BELGIUM CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)

TABLE 194 BELGIUM CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 195 BELGIUM CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 196 BELGIUM CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 197 BELGIUM MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 198 BELGIUM AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 199 BELGIUM CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)

TABLE 200 BELGIUM CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)

TABLE 201 BELGIUM CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)

TABLE 202 BELGIUM CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)

TABLE 203 BELGIUM CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)

TABLE 204 TURKEY CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)

TABLE 205 TURKEY CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 206 TURKEY CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 207 TURKEY CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 208 TURKEY MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 209 TURKEY AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 210 TURKEY CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)

TABLE 211 TURKEY CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)

TABLE 212 TURKEY CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)

TABLE 213 TURKEY CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)

TABLE 214 TURKEY CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)

TABLE 215 AUSTRIA CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)

TABLE 216 AUSTRIA CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 217 AUSTRIA CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 218 AUSTRIA CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 219 AUSTRIA MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 220 AUSTRIA AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 221 AUSTRIA CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)

TABLE 222 AUSTRIA CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)

TABLE 223 AUSTRIA CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)

TABLE 224 AUSTRIA CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)

TABLE 225 AUSTRIA CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)

TABLE 226 NORWAY CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)

TABLE 227 NORWAY CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 228 NORWAY CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 229 NORWAY CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 230 NORWAY MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 231 NORWAY AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 232 NORWAY CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)

TABLE 233 NORWAY CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)

TABLE 234 NORWAY CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)

TABLE 235 NORWAY CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)

TABLE 236 NORWAY CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)

TABLE 237 HUNGARY CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)

TABLE 238 HUNGARY CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 239 HUNGARY CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 240 HUNGARY CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 241 HUNGARY MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 242 HUNGARY AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 243 HUNGARY CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)

TABLE 244 HUNGARY CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)

TABLE 245 HUNGARY CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)

TABLE 246 HUNGARY CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)

TABLE 247 HUNGARY CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)

TABLE 248 LITHUANIA CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)

TABLE 249 LITHUANIA CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 250 LITHUANIA CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 251 LITHUANIA CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 252 LITHUANIA MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 253 LITHUANIA AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 254 LITHUANIA CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)

TABLE 255 LITHUANIA CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)

TABLE 256 LITHUANIA CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)

TABLE 257 LITHUANIA CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)

TABLE 258 LITHUANIA CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)

TABLE 259 IRELAND CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)

TABLE 260 IRELAND CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 261 IRELAND CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 262 IRELAND CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 263 IRELAND MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 264 IRELAND AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 265 IRELAND CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)

TABLE 266 IRELAND CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)

TABLE 267 IRELAND CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)

TABLE 268 IRELAND CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)

TABLE 269 IRELAND CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)

TABLE 270 POLAND CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)

TABLE 271 POLAND CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 272 POLAND CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 273 POLAND CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 274 POLAND MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 275 POLAND AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 276 POLAND CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)

TABLE 277 POLAND CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)

TABLE 278 POLAND CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)

TABLE 279 POLAND CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)

TABLE 280 POLAND CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)

TABLE 281 REST OF EUROPE CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)

TABLE 282 ASIA-PACIFIC CYCLODEXTRINS IN PHARMA MARKET, BY COUNTRY, 2018-2027 (USD THOUSAND)

TABLE 283 ASIA-PACIFIC CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)

TABLE 284 ASIA-PACIFIC CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 285 ASIA-PACIFIC CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 286 ASIA-PACIFIC CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 287 ASIA-PACIFIC MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 288 ASIA-PACIFIC AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 289 ASIA-PACIFIC CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)

TABLE 290 ASIA-PACIFIC CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)

TABLE 291 ASIA-PACIFIC CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)

TABLE 292 ASIA-PACIFIC CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)

TABLE 293 ASIA-PACIFIC CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)

TABLE 294 JAPAN CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)

TABLE 295 JAPAN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 296 JAPAN CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 297 JAPAN CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 298 JAPAN MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 299 JAPAN AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 300 JAPAN CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)

TABLE 301 JAPAN CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)

TABLE 302 JAPAN CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)

TABLE 303 JAPAN CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)

TABLE 304 JAPAN CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)

TABLE 305 CHINA CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)

TABLE 306 CHINA CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 307 CHINA CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 308 CHINA CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 309 CHINA MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 310 CHINA AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 311 CHINA CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)

TABLE 312 CHINA CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)

TABLE 313 CHINA CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)

TABLE 314 CHINA CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)

TABLE 315 CHINA CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)

TABLE 316 INDIA CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)

TABLE 317 INDIA CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 318 INDIA CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 319 INDIA CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 320 INDIA MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 321 INDIA AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 322 INDIA CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)

TABLE 323 INDIA CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)

TABLE 324 INDIA CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)

TABLE 325 INDIA CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)

TABLE 326 INDIA CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)

TABLE 327 SOUTH KOREA CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)

TABLE 328 SOUTH KOREA CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 329 SOUTH KOREA CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 330 SOUTH KOREA CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 331 SOUTH KOREA MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 332 SOUTH KOREA AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 333 SOUTH KOREA CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)

TABLE 334 SOUTH KOREA CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)

TABLE 335 SOUTH KOREA CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)

TABLE 336 SOUTH KOREA CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)

TABLE 337 SOUTH KOREA CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)

TABLE 338 AUSTRALIA CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)

TABLE 339 AUSTRALIA CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 340 AUSTRALIA CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 341 AUSTRALIA CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 342 AUSTRALIA MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 343 AUSTRALIA AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 344 AUSTRALIA CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)

TABLE 345 AUSTRALIA CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)

TABLE 346 AUSTRALIA CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)

TABLE 347 AUSTRALIA CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)

TABLE 348 AUSTRALIA CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)

TABLE 349 SINGAPORE CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)

TABLE 350 SINGAPORE CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 351 SINGAPORE CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 352 SINGAPORE CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 353 SINGAPORE MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 354 SINGAPORE AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 355 SINGAPORE CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)

TABLE 356 SINGAPORE CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)

TABLE 357 SINGAPORE CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)

TABLE 358 SINGAPORE CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)

TABLE 359 SINGAPORE CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)

TABLE 360 MALAYSIA CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)

TABLE 361 MALAYSIA CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 362 MALAYSIA CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 363 MALAYSIA CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 364 MALAYSIA MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 365 MALAYSIA AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 366 MALAYSIA CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)

TABLE 367 MALAYSIA CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)

TABLE 368 MALAYSIA CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)

TABLE 369 MALAYSIA CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)

TABLE 370 MALAYSIA CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)

TABLE 371 THAILAND CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)

TABLE 372 THAILAND CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 373 THAILAND CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 374 THAILAND CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 375 THAILAND MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 376 THAILAND AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 377 THAILAND CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)

TABLE 378 THAILAND CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)

TABLE 379 THAILAND CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)

TABLE 380 THAILAND CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)

TABLE 381 THAILAND CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)

TABLE 382 INDONESIA CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)

TABLE 383 INDONESIA CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 384 INDONESIA CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 385 INDONESIA CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 386 INDONESIA MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 387 INDONESIA AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 388 INDONESIA CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)

TABLE 389 INDONESIA CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)

TABLE 390 INDONESIA CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)

TABLE 391 INDONESIA CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)

TABLE 392 INDONESIA CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)

TABLE 393 PHILIPPINES CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)

TABLE 394 PHILIPPINES CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 395 PHILIPPINES CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 396 PHILIPPINES CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 397 PHILIPPINES MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 398 PHILIPPINES AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 399 PHILIPPINES CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)

TABLE 400 PHILIPPINES CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)

TABLE 401 PHILIPPINES CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)

TABLE 402 PHILIPPINES CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)

TABLE 403 PHILIPPINES CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)

TABLE 404 VIETNAM CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)

TABLE 405 VIETNAM CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 406 VIETNAM CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 407 VIETNAM CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 408 VIETNAM MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 409 VIETNAM AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 410 VIETNAM CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)

TABLE 411 VIETNAM CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)

TABLE 412 VIETNAM CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)

TABLE 413 VIETNAM CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)

TABLE 414 VIETNAM CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)

TABLE 415 REST OF ASIA-PACIFIC CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)

TABLE 416 SOUTH AMERICA CYCLODEXTRINS IN PHARMA MARKET, BY COUNTRY, 2018-2027 (USD THOUSAND)

TABLE 417 SOUTH AMERICA CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)

TABLE 418 SOUTH AMERICA CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 419 SOUTH AMERICA CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 420 SOUTH AMERICA CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 421 SOUTH AMERICA MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 422 SOUTH AMERICA AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 423 SOUTH AMERICA CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)

TABLE 424 SOUTH AMERICA CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)

TABLE 425 SOUTH AMERICA CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)

TABLE 426 SOUTH AMERICA CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)

TABLE 427 SOUTH AMERICA CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)

TABLE 428 BRAZIL CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)

TABLE 429 BRAZIL CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 430 BRAZIL CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 431 BRAZIL CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 432 BRAZIL MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 433 BRAZIL AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 434 BRAZIL CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)

TABLE 435 BRAZIL CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)

TABLE 436 BRAZIL CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)

TABLE 437 BRAZIL CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)

TABLE 438 BRAZIL CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)

TABLE 439 ARGENTINA CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)

TABLE 440 ARGENTINA CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 441 ARGENTINA CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 442 ARGENTINA CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 443 ARGENTINA MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 444 ARGENTINA AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 445 ARGENTINA CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)

TABLE 446 ARGENTINA CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)

TABLE 447 ARGENTINA CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)

TABLE 448 ARGENTINA CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)

TABLE 449 ARGENTINA CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)

TABLE 450 PERU CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)

TABLE 451 PERU CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 452 PERU CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 453 PERU CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 454 PERU MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 455 PERU AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 456 PERU CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)

TABLE 457 PERU CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)

TABLE 458 PERU CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)

TABLE 459 PERU CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)

TABLE 460 PERU CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)

TABLE 461 REST OF SOUTH AMERICA CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)

TABLE 462 MIDDLE EAST & AFRICA CYCLODEXTRINS IN PHARMA MARKET, BY COUNTRY, 2018-2027 (USD THOUSAND)

TABLE 463 MIDDLE EAST & AFRICA CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)

TABLE 464 MIDDLE EAST & AFRICA CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 465 MIDDLE EAST & AFRICA CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 466 MIDDLE EAST & AFRICA CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 467 MIDDLE EAST & AFRICA MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 468 MIDDLE EAST & AFRICA AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 469 MIDDLE EAST & AFRICA CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)

TABLE 470 MIDDLE EAST & AFRICA CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)

TABLE 471 MIDDLE EAST & AFRICA CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)

TABLE 472 MIDDLE EAST & AFRICA CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)

TABLE 473 MIDDLE EAST & AFRICA CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)

TABLE 474 SAUDI ARABIA CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)

TABLE 475 SAUDI ARABIA CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 476 SAUDI ARABIA CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 477 SAUDI ARABIA CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 478 SAUDI ARABIA MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 479 SAUDI ARABIA AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 480 SAUDI ARABIA CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)

TABLE 481 SAUDI ARABIA CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)

TABLE 482 SAUDI ARABIA CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)

TABLE 483 SAUDI ARABIA CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)

TABLE 484 SAUDI ARABIA CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)

TABLE 485 SOUTH AFRICA CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)

TABLE 486 SOUTH AFRICA CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 487 SOUTH AFRICA CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 488 SOUTH AFRICA CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 489 SOUTH AFRICA MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 490 SOUTH AFRICA AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 491 SOUTH AFRICA CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)

TABLE 492 SOUTH AFRICA CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)

TABLE 493 SOUTH AFRICA CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)

TABLE 494 SOUTH AFRICA CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)

TABLE 495 SOUTH AFRICA CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)

TABLE 496 UAE CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)

TABLE 497 UAE CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 498 UAE CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 499 UAE CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 500 UAE MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 501 UAE AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 502 UAE CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)

TABLE 503 UAE CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)

TABLE 504 UAE CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)

TABLE 505 UAE CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)

TABLE 506 UAE CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)

TABLE 507 ISRAEL CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)

TABLE 508 ISRAEL CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 509 ISRAEL CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 510 ISRAEL CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 511 ISRAEL MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 512 ISRAEL AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 513 ISRAEL CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)

TABLE 514 ISRAEL CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)

TABLE 515 ISRAEL CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)

TABLE 516 ISRAEL CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)

TABLE 517 ISRAEL CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)

TABLE 518 EGYPT CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)

TABLE 519 EGYPT CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 520 EGYPT CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 521 EGYPT CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 522 EGYPT MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 523 EGYPT AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 524 EGYPT CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)

TABLE 525 EGYPT CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)

TABLE 526 EGYPT CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)

TABLE 527 EGYPT CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)

TABLE 528 EGYPT CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)

TABLE 529 KUWAIT CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)

TABLE 530 KUWAIT CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 531 KUWAIT CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 532 KUWAIT CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 533 KUWAIT MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 534 KUWAIT AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)

TABLE 535 KUWAIT CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)

TABLE 536 KUWAIT CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)

TABLE 537 KUWAIT CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)

TABLE 538 KUWAIT CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)

TABLE 539 KUWAIT CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)

TABLE 540 REST OF MIDDLE EAST & AFRICA CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)

 

Abbildungsverzeichnis

LIST OF FIGURES 

FIGURE 1 GLOBAL CYCLODEXTRINS IN PHARMA MARKET: SEGMENTATION

FIGURE 2 GLOBAL CYCLODEXTRINS IN PHARMA MARKET : DATA TRIANGULATION

FIGURE 3 GLOBAL CYCLODEXTRINS IN PHARMA MARKET: DROC ANALYSIS

FIGURE 4 GLOBAL CYCLODEXTRINS IN PHARMA MARKET: GLOBAL VS REGIONAL MARKET ANALYSIS

FIGURE 5 GLOBAL CYCLODEXTRINS IN PHARMA MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 GLOBAL CYCLODEXTRINS IN PHARMA MARKET: MULTIVARIATE MODELLING

FIGURE 7 GLOBAL CYCLODEXTRINS IN PHARMA MARKET: MARKET APPLICATION COVERAGE GRID

FIGURE 8 GLOBAL CYCLODEXTRINS IN PHARMA MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 9 GLOBAL CYCLODEXTRINS IN PHARMA MARKET: DBMR MARKET POSITION GRID

FIGURE 10 GLOBAL CYCLODEXTRINS IN PHARMA MARKET: VENDOR SHARE ANALYSIS

FIGURE 11 GLOBAL CYCLODEXTRINS IN PHARMA MARKET: SEGMENTATION

FIGURE 12 NORTH AMERICA IS EXPECTED TO DOMINATE THE GLOBAL CYCLODEXTRINS IN PHARMA MARKET IN THE FORECAST PERIOD OF 2020 TO 2027

FIGURE 13 INCREASING BIO AVAILABILITY OF POOR WATER SOLUBLE DRUGS AND INCREASES DRUG STABILITY IS DRIVING THE GLOBAL CYCLODEXTRINS IN PHARMA MARKET IN THE FORECAST PERIOD OF 2020 TO 2027

FIGURE 14 B CYCLODEXTRIN SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL CYCLODEXTRINS IN PHARMA MARKET IN 2020 & 2027

FIGURE 15 ASIA-PACIFIC IS THE FASTEST GROWING MARKET IN GLOBAL CYCLODEXTRINS IN PHARMA MARKET IN THE FORECAST PERIOD OF 2020 TO 2027

FIGURE 16 GLOBAL CYCLODEXTRINS IN PHARMA MARKET, PIPELINE ANALYSIS

FIGURE 17 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF GLOBAL CYCLODEXTRINS IN PHARMA MARKET

FIGURE 18 GLOBAL CYCLODEXTRINS IN PHARMA MARKET: BY TYPE, 2019

FIGURE 19 GLOBAL CYCLODEXTRINS IN PHARMA MARKET: BY TYPE, 2019-2027 (USD THOUSAND)

FIGURE 20 GLOBAL CYCLODEXTRINS IN PHARMA MARKET: BY TYPE, CAGR (2020-2027)

FIGURE 21 GLOBAL CYCLODEXTRINS IN PHARMA MARKET: BY TYPE, LIFELINE CURVE

FIGURE 22 GLOBAL CYCLODEXTRINS IN PHARMA MARKET: BY STRUCTURE, 2019

FIGURE 23 GLOBAL CYCLODEXTRINS IN PHARMA MARKET: BY STRUCTURE, 2019-2027 (USD THOUSAND)

FIGURE 24 GLOBAL CYCLODEXTRINS IN PHARMA MARKET: BY STRUCTURE, CAGR (2020-2027)

FIGURE 25 GLOBAL CYCLODEXTRINS IN PHARMA MARKET: BY STRUCTURE, LIFELINE CURVE

FIGURE 26 GLOBAL CYCLODEXTRINS IN PHARMA MARKET: BY FORM, 2019

FIGURE 27 GLOBAL CYCLODEXTRINS IN PHARMA MARKET: BY FORM, 2019-2027 (USD THOUSAND)

FIGURE 28 GLOBAL CYCLODEXTRINS IN PHARMA MARKET: BY FORM, CAGR (2020-2027)

FIGURE 29 GLOBAL CYCLODEXTRINS IN PHARMA MARKET: BY FORM, LIFELINE CURVE

FIGURE 30 GLOBAL CYCLODEXTRINS IN PHARMA MARKET: BY NATURE, 2019

FIGURE 31 GLOBAL CYCLODEXTRINS IN PHARMA MARKET: BY NATURE, 2019-2027 (USD THOUSAND)

FIGURE 32 GLOBAL CYCLODEXTRINS IN PHARMA MARKET: BY NATURE, CAGR (2020-2027)

FIGURE 33 GLOBAL CYCLODEXTRINS IN PHARMA MARKET: BY NATURE, LIFELINE CURVE

FIGURE 34 GLOBAL CYCLODEXTRINS IN PHARMA MARKET: BY APPLICATION, 2019

FIGURE 35 GLOBAL CYCLODEXTRINS IN PHARMA MARKET: BY APPLICATION, 2019-2027 (USD THOUSAND)

FIGURE 36 GLOBAL CYCLODEXTRINS IN PHARMA MARKET: BY APPLICATION, CAGR (2020-2027)

FIGURE 37 GLOBAL CYCLODEXTRINS IN PHARMA MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 38 GLOBAL CYCLODEXTRINS IN PHARMA MARKET: BY THERAPEUTIC AREAS, 2019

FIGURE 39 GLOBAL CYCLODEXTRINS IN PHARMA MARKET: BY THERAPEUTIC AREAS, 2019-2027 (USD THOUSAND)

FIGURE 40 GLOBAL CYCLODEXTRINS IN PHARMA MARKET: BY THERAPEUTIC AREAS, CAGR (2020-2027)

FIGURE 41 GLOBAL CYCLODEXTRINS IN PHARMA MARKET: BY THERAPEUTIC AREAS, LIFELINE CURVE

FIGURE 42 GLOBAL CYCLODEXTRINS IN PHARMA MARKET: BY DISTRIBUTION CHANNEL, 2019

FIGURE 43 GLOBAL CYCLODEXTRINS IN PHARMA MARKET: BY DISTRIBUTION CHANNEL, 2019-2027 (USD THOUSAND)

FIGURE 44 GLOBAL CYCLODEXTRINS IN PHARMA MARKET: BY DISTRIBUTION CHANNEL, CAGR (2020-2027)

FIGURE 45 GLOBAL CYCLODEXTRINS IN PHARMA MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 46 GLOBAL CYCLODEXTRINS IN PHARMA MARKET: SNAPSHOT (2019)

FIGURE 47 GLOBAL CYCLODEXTRINS IN PHARMA MARKET: BY REGION (2019)

FIGURE 48 GLOBAL CYCLODEXTRINS IN PHARMA MARKET: BY REGION (2020 & 2027)

FIGURE 49 GLOBAL CYCLODEXTRINS IN PHARMA MARKET: BY REGION (2019 & 2027)

FIGURE 50 GLOBAL CYCLODEXTRINS IN PHARMA MARKET: BY TYPE (2020-2027)

FIGURE 51 NORTH AMERICA CYCLODEXTRINS IN PHARMA MARKET: SNAPSHOT (2019)

FIGURE 52 NORTH AMERICA CYCLODEXTRINS IN PHARMA MARKET: BY COUNTRY (2019)

FIGURE 53 NORTH AMERICA CYCLODEXTRINS IN PHARMA MARKET: BY COUNTRY (2020 & 2027)

FIGURE 54 NORTH AMERICA CYCLODEXTRINS IN PHARMA MARKET: BY COUNTRY (2019 & 2027)

FIGURE 55 NORTH AMERICA CYCLODEXTRINS IN PHARMA MARKET: BY TYPE (2020-2027)

FIGURE 56 EUROPE CYCLODEXTRINS IN PHARMA MARKET: SNAPSHOT (2019)

FIGURE 57 EUROPE CYCLODEXTRINS IN PHARMA MARKET: BY COUNTRY (2019)

FIGURE 58 EUROPE CYCLODEXTRINS IN PHARMA MARKET: BY COUNTRY (2020 & 2027)

FIGURE 59 EUROPE CYCLODEXTRINS IN PHARMA MARKET: BY COUNTRY (2019 & 2027)

FIGURE 60 EUROPE CYCLODEXTRINS IN PHARMA MARKET: BY TYPE (2020-2027)

FIGURE 61 ASIA-PACIFIC CYCLODEXTRINS IN PHARMA MARKET: SNAPSHOT (2019)

FIGURE 62 ASIA-PACIFIC CYCLODEXTRINS IN PHARMA MARKET: BY COUNTRY (2019)

FIGURE 63 ASIA-PACIFIC CYCLODEXTRINS IN PHARMA MARKET: BY COUNTRY (2020 & 2027)

FIGURE 64 ASIA-PACIFIC CYCLODEXTRINS IN PHARMA MARKET: BY COUNTRY (2019 & 2027)

FIGURE 65 ASIA-PACIFIC CYCLODEXTRINS IN PHARMA MARKET: BY TYPE (2020-2027)

FIGURE 66 SOUTH AMERICA CYCLODEXTRINS IN PHARMA MARKET: SNAPSHOT (2019)

FIGURE 67 SOUTH AMERICA CYCLODEXTRINS IN PHARMA MARKET: BY COUNTRY (2019)

FIGURE 68 SOUTH AMERICA CYCLODEXTRINS IN PHARMA MARKET: BY COUNTRY (2020 & 2027)

FIGURE 69 SOUTH AMERICA CYCLODEXTRINS IN PHARMA MARKET: BY COUNTRY (2019 & 2027)

FIGURE 70 SOUTH AMERICA CYCLODEXTRINS IN PHARMA MARKET: BY TYPE (2020-2027)

FIGURE 71 MIDDLE EAST & AFRICA CYCLODEXTRINS IN PHARMA MARKET: SNAPSHOT (2019)

FIGURE 72 MIDDLE EAST & AFRICA CYCLODEXTRINS IN PHARMA MARKET: BY COUNTRY (2019)

FIGURE 73 MIDDLE EAST & AFRICA CYCLODEXTRINS IN PHARMA MARKET: BY COUNTRY (2020 & 2027)

FIGURE 74 MIDDLE EAST & AFRICA CYCLODEXTRINS IN PHARMA MARKET: BY COUNTRY (2019 & 2027)

FIGURE 75 MIDDLE EAST & AFRICA CYCLODEXTRINS IN PHARMA MARKET: BY TYPE (2020-2027)

FIGURE 76 GLOBAL CYCLODEXTRINS IN PHARMA MARKET: COMPANY SHARE 2019 (%)

FIGURE 77 NORTH AMERICA CYCLODEXTRINS IN PHARMA MARKET: COMPANY SHARE 2019 (%)

FIGURE 78 EUROPE CYCLODEXTRINS IN PHARMA MARKET: COMPANY SHARE 2019 (%)

FIGURE 79 ASIA-PACIFIC CYCLODEXTRINS IN PHARMA MARKETMARKET: COMPANY SHARE 2019 (%)

 

Detaillierte Informationen anzeigen Right Arrow

Forschungsmethodik

Die Datenerfassung und Basisjahresanalyse werden mithilfe von Datenerfassungsmodulen mit großen Stichprobengrößen durchgeführt. Die Phase umfasst das Erhalten von Marktinformationen oder verwandten Daten aus verschiedenen Quellen und Strategien. Sie umfasst die Prüfung und Planung aller aus der Vergangenheit im Voraus erfassten Daten. Sie umfasst auch die Prüfung von Informationsinkonsistenzen, die in verschiedenen Informationsquellen auftreten. Die Marktdaten werden mithilfe von marktstatistischen und kohärenten Modellen analysiert und geschätzt. Darüber hinaus sind Marktanteilsanalyse und Schlüsseltrendanalyse die wichtigsten Erfolgsfaktoren im Marktbericht. Um mehr zu erfahren, fordern Sie bitte einen Analystenanruf an oder geben Sie Ihre Anfrage ein.

Die wichtigste Forschungsmethodik, die vom DBMR-Forschungsteam verwendet wird, ist die Datentriangulation, die Data Mining, die Analyse der Auswirkungen von Datenvariablen auf den Markt und die primäre (Branchenexperten-)Validierung umfasst. Zu den Datenmodellen gehören ein Lieferantenpositionierungsraster, eine Marktzeitlinienanalyse, ein Marktüberblick und -leitfaden, ein Firmenpositionierungsraster, eine Patentanalyse, eine Preisanalyse, eine Firmenmarktanteilsanalyse, Messstandards, eine globale versus eine regionale und Lieferantenanteilsanalyse. Um mehr über die Forschungsmethodik zu erfahren, senden Sie eine Anfrage an unsere Branchenexperten.

Anpassung möglich

Data Bridge Market Research ist ein führendes Unternehmen in der fortgeschrittenen formativen Forschung. Wir sind stolz darauf, unseren bestehenden und neuen Kunden Daten und Analysen zu bieten, die zu ihren Zielen passen. Der Bericht kann angepasst werden, um Preistrendanalysen von Zielmarken, Marktverständnis für zusätzliche Länder (fordern Sie die Länderliste an), Daten zu klinischen Studienergebnissen, Literaturübersicht, Analysen des Marktes für aufgearbeitete Produkte und Produktbasis einzuschließen. Marktanalysen von Zielkonkurrenten können von technologiebasierten Analysen bis hin zu Marktportfoliostrategien analysiert werden. Wir können so viele Wettbewerber hinzufügen, wie Sie Daten in dem von Ihnen gewünschten Format und Datenstil benötigen. Unser Analystenteam kann Ihnen auch Daten in groben Excel-Rohdateien und Pivot-Tabellen (Fact Book) bereitstellen oder Sie bei der Erstellung von Präsentationen aus den im Bericht verfügbaren Datensätzen unterstützen.

Häufig gestellte Fragen

The market value for Cyclodextrins in Pharma Market is expected USD 370.06 million by 2029.
The Cyclodextrins in Pharma Market is to grow at a CAGR of 4.00% during the forecast by 2029.
On the basis of application, the Cyclodextrins in Pharma Market is segmented into Drug Solubility and Dissolution, Drug Bioavailability, Drug Safety, Drug Stability, Others.
The major players operating in the Cyclodextrins in Pharma Market are Cambrex Corporation (US), Cayman Chemical (US), Wellona Pharma (India), Wacker Chemie AG (Germany), Cyclolab (Hungary), Tocopharm Co. Limited (China), Roquette Frères (France), Midas Pharma GmbH (Germany), Ligand Pharmaceuticals Incorporated (US), Cyclo Therapeutics, Inc. (US), Zibo Qianhui biological technology co., ltd (China), Xi'an Deli Biochemical Industry Co., Ltd (China), Merck KGaA (Germany), Otto Chemie Pvt. Ltd. (India), VIO CHEMICALS (Switzerland), Ashland (US), TCI Chemicals (India) Pvt. Ltd. (Japan).